US5175155A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Win 49596-finasteride method of use and compositions
Assignee: Sanofi SA
•
Filing: 1991-10-07
•
Granted: 1992-12-29
•
Expires: 2011-10-07
Abstract
Abstract The method of use of a combination of the antiandrogen (5 alpha ,17 alpha )-1'-(methylsulfonyl)-1'H-pregn-20-yno[3,2-c]pyrazol-17-ol (Win 49596) and the 5 alpha -reductase inhibitor (5 alpha ,17 beta )-N-(1,1-dimethylethyl)-3-oxo-4-azaandrost-1-ene-17-carboxamide (finasteride) for treating prostate disease in a male mammal and pharmaceutical compositions thereof are disclosed.
Inventors
- 👤 Paul E. Juniewicz
- 👤 Bruce M. Berger
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-28 04:37
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/56; A61K31/58; A61P; A61P13/00; A61P13/02; A61P15/00
Claims Analysis
Total Claims: 8
Claim 1
Independent Claim
41 words
The method of reducing the size or inhibiting the growth of the prostate in a male mammal which comprises administering to the mammal a combination of (5α, 17α)-1'-(methylsulfonyl)-1'H-pregn-20-yno[3,2-c]pyrazol17-ol and (5α,17β)-N-(1,1-dimethylethyl)-3-oxo-4-azaandrost-1-ene-17-carboxamide in a weight ratio in the range from 100:1 to 1:1.
Claim 2
Independent Claim
41 words
The method of reducing the size or inhibiting the growth of the prostate in a male mammal which comprises administering to the mammal a combination of (5α, 17α)-1'-(methylsulfonyl)-1'H-pregn-20-yno[3,2-c]pyrazol17-ol and (5α,17β)-N-(1,1-dimethylethyl)-3-oxo-4-azaandrost-1-ene-17-carboxamide in a weight ratio in the range from 100:1 to 1:1.
Claim 3
Dependent Claim
22 words
The method according to claim 1 wherein the weight ratio of (5α,17α)-1'-(methylsulfonyl)-1'H-pregn-20-yno[3,2-c]pyrazol-17-ol and (5α,17β)-N-(1,1-dimethylethyl)-3-oxo-4-azaandrost-1-ene-17-carboxamide is in the range from 50:1 to 5:1.
Claim 4
Dependent Claim
26 words
A pharmaceutical composition which comprises a combination of (5α,17α)-1'-(methylsulfonyl)-1'H-pregn-20-yno[3,2-c]pyrazol-17-ol and (5α,17β)-N-(1,1-dimethylethyl)-3-oxo-4-azaandrost-1-ene-17-carboxamide in a weight ratio in the range from 100:1 to 1:1 in a pharmaceutical vehicle.
Claim 5
Dependent Claim
26 words
A pharmaceutical composition which comprises a combination of (5α,17α)-1'-(methylsulfonyl)-1'H-pregn-20-yno[3,2-c]pyrazol-17-ol and (5α,17β)-N-(1,1-dimethylethyl)-3-oxo-4-azaandrost-1-ene-17-carboxamide in a weight ratio in the range from 100:1 to 1:1 in a pharmaceutical vehicle.
Claim 6
Dependent Claim
26 words
A pharmaceutical composition according to claim 3 wherein the weight ratio of (5α,17α)-1'-(methylsulfonyl)-1'H-pregn-20-yno[3,2-c]pyrazol-17-ol and (5α,17β)-N-(1,1-dimethylethyl)-3-oxo-4-azaandrost-1-ene-17-carboxamide in the composition is in the range from 50:1 to 1:1.
Claim 7
Dependent Claim
33 words
The method of reducing the size or inhibiting the growth of the prostate in a male mammal which comprises administering to the mammal an effective amount of a composition according to claim 3.
Claim 8
Dependent Claim
33 words
The method of reducing the size or inhibiting the growth of the prostate in a male mammal which comprises administering to the mammal an effective amount of a composition according to claim 4.
References Cited (Backward Citations)
US4760071A
Cited
US4684636A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1995-12-29 | 1996-06-29 | 1996-12-29 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1999-12-29 | 2000-06-29 | 2000-12-29 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2003-12-29 | 2004-06-29 | 2004-12-29 | $7700.00 | Window Closed / Lapsed |